ArticlePloS one2025
Predicting prostate cancer metastasis in Ghana: Comparison of multiparametric and PSA models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Urinary Epithelial Cell Adhesion Molecule (EpCAM) as a Noninvasive Biomarker for Detecting Clinically Significant Prostate Cancer in Men With Equivocal PSA Levels.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is the most prevalent male malignancy in Ghana, with a high-risk of metastatic progression. Early detection and adequate disease severity stratification are crucial for timely intervention, comprehensive management, and improved outcomes. This study evaluates and compares the predictive abilities of a multiparametric model and a PSA-alone model in forecasting metastasis in prostate cancer patients.
objectiveTo compare the performance of a multiparametric model and a PSA-alone model in predicting metastasis in prostate cancer patients in Ghana. METHODOLOGY: Logistic regression analyses were conducted on a dataset of 426 prostate cancer cases. The multiparametric model included variables such as age, BMI, marital status, ethnicity, socioeconomic status, clinical stage by DRE findings, PSA levels, and Gleason score. The PSA-alone model focused solely on PSA levels. Model performance metrics included Pseudo R-Squared, AUC, sensitivity, specificity, accuracy, PPV, NPV, FPR, FNR, and F1-Score. The Hosmer-Lemeshow test assessed the goodness-of-fit for the multiparametric model. All analyses were conducted at a 5% level of significance.
resultsThe multiparametric model achieved a Pseudo R-Squared of 71.17%, AUC of 97.18%, sensitivity of 93.20%, specificity of 96.21%, accuracy of 92.25%, PPV of 85.62%, NPV of 96.24%, FPR of 8.24%, FNR of 6.80%, and F1-Score of 81.02%. The Hosmer-Lemeshow test yielded a non-significant p-value of 0.2405. The PSA-alone model had sensitivity of 32.24%, specificity of 91.76%, accuracy of 88.03%, PPV of 77.47%, NPV of 92.02%, FPR of 3.79%, FNR of 67.76%, F1-Score of 45.76%, and AUC of 73.79%. The multiparametric model's Prevalence Yield was 32.15% and Sensitivity Yield was 32.15%, compared to the PSA-alone model's 6.95% and 13.32%, respectively.
conclusionBoth models effectively predict metastasis in prostate cancer patients. The multiparametric model shows superior overall performance with higher Pseudo R-Squared, AUC, and a better balance in sensitivity, specificity, and accuracy. These results suggest the multiparametric model as a more robust tool for metastasis risk assessment in resource-poor settings. However, clinical context and patient characteristics should guide model choice for optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.